47 / 88
47
Tuesday, 20 June 2017
/ Scientific Programme
WFSBP 2017
TUE
002
Insulin resistance in neurodegeneration: The role
of p53 /miRNA/ SIRT1 axis
Kazimierz Gasiorowski, Poland
003
Alzheimer drug discovery: Targeting synaptic
glutamate signaling
Markku Kurkinen, USA
004
Nanotechnology for early detection and treatment
of Alzheimer's Disease (AD): Where we stand
and where we go?
Jerzy Leszek, Poland
T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)
S-41
SYMPOSIUM
15:00–16:30
B3 M3-M4
Electroconvulsive therapy for depression – optimising
treatment and maintaining recovery
Chair:
Declan McLoughlin, Ireland
Co-Chair: Pascal Sienaert, Belgium
001
The KEEP-WELL Trial: Ketamine for depression
relapse prevention following ECT (NCT02414932)
Declan McLoughlin, Ireland
002
Immediate and long-term outcomes for Brief-pulse
(BP) vs Ultrabrief-pulse (UBP) high-dose unilateral ECT:
The ResPECT trials' experience
Pascal Sienaert, Belgium
H.-P. Spaans, E. Verwijk, F. Bouckaert
003
Pre- and post-ECT cognitive performance as
predictors for outcome and relapse in depression
(NTR1304)
Esmée Verwijk, The Netherlands
004
The PRIDE Trial – Prolonging remission in
depressed elderly (NCT01028508): Results from the
randomised phase
Charles Kellner, USA
T11: DEPRESSION: BASIC/ CLINICAL
WS-07
WORKSHOP
15:00–16:30
Auditorium 15
Merging evidence and clinical practice in management
of depression: The CANMAT experience
Chair:
Sidney Kennedy, Canada
Co-Chair: Roumen Milev, Canada
001
Guidelines for pharmacological management of
depression
Raymond Lam, Canada
002
Making effective guidelines: Examples of evidence-
based dissemination and implementation strategies
Sagar Parikh, USA
003
Guidelines for the treatment of depression in
specific populations: Making decisions despite gaps in
evidence
Glenda MacQueen, Canada
004
Guidelines for the use of Complementary and
Alternative Medicines ( CAM ) in major depression
Arun Ravindran, Canada
T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)
TFS-06
WFSBP TASK FORCE SYMPOSIUM
17:00–18:30
Auditorium 12
Electroconvulsive therapy: Beyond depression
Chair:
Georgios Petrides, USA
Co-Chair: William McDonald, USA
001
ECT for the treatment of catatonia
Tom Bolwig, Denmark
002
ECT in autism spectrum disorders: Catatonia and
beyond
Lee Wachtel, USA
003
ECT for agitation in elderly patients with dementia
Adriana Hermida, USA
004
ECT-related mortality rates
Søren Dinesen Østergaard, Denmark
T22: MOLECULAR NEUROBIOLOGY
S-42
SYMPOSIUM
17:00–18:30
Congress Hall A 3
Neuroepigenetic approaches to assess disease risk,
mechanism and treatment
Chair:
Alfonso Buil, Denmark
Co-Chair: Jonathan Mill, United Kingdom
001
CACNA1C hypermethylation associated with
Bipolar Disorder (BD)
Anna Starnawska, Denmark
D. Demontis, A. Pen, A. Hedemand, A. L. Nielsen,
N. H. Staunstrup, J. Grove, T. D. Als, A. Jarram,
N. L. O'Brien, O. Mors, A. McQuillin, A. Børglum
002
Epigenomic trajectories across human brain devel-
opment: Relevance for schizophrenia and other neuro-
developmental disorders
Jonathan Mill, United Kingdom